OMB Individually Reported

AI for Assessing Bioanalytical Study Conduct Alignment with Guidance and Method SOPs

Low riskExact public inventory row

Description

Cross-comparing large amounts of bioanalytical data (reports, validation, tabulated data) with the M10 guidance and aligned method Standard Operating Procedures (SOPs) to identify all possible study conduct issues.

Detailed example

Organized summary of bioanalytical study conduct deviations from M10 principles, regulations, and method SOPs, followed by a summary of potential study impact. Outputs are verified by FDA staff.

AI / analytics pattern

Generative AI: AI that generates new or synthetic content (e.g., images, videos, audio, text, code).

Automation level / stage

b) Pilot – The use case has been deployed in a limited test or pilot capacity.

Expected benefit

Expedited identification of bioanalytical study conduct issues through efficient cross-comparisons between the M10 guidance, method Standard Operating Procedures (SOPs), and bioanalytical study reports/data before and during inspections, helping ensure data quality and regulatory compliance.

Controls / human review

ATO: Yes; PIA: Not published

Data needed

No FDA data were used to train, fine-tune or evaluate